We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Algeta Announces First Sale of Xofigo® in the United States
News

Algeta Announces First Sale of Xofigo® in the United States

Algeta Announces First Sale of Xofigo® in the United States
News

Algeta Announces First Sale of Xofigo® in the United States

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Algeta Announces First Sale of Xofigo® in the United States"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Algeta ASA has announced that Xofigo® (radium Ra 223 dichloride) injection, recently approved by the US Food and Drug Administration (FDA) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease, has been launched in the United States and the first sale has been made.

The first commercial sale of Xofigo triggers a EUR 50 million milestone payment to Algeta from Bayer under the terms of the 2009 development and licensing agreement.

Bayer has worldwide exclusive marketing rights for Xofigo. Algeta US, LLC and Bayer Healthcare are co-promoting the product in the US.

Algeta’s President & CEO, Andrew Kay, commented: “We are delighted to announce the first sale of Xofigo, following its approval by the FDA. The development of bone metastases is a frequent consequence in men with castration-resistant prostate cancer, and is a major cause of disability and death in this disease. These patients have limited therapeutic options and we anticipate that Xofigo will be an important and welcome new addition to the treatment paradigm.”

Advertisement